Showing results (21-30 of 88) with videos related to

Sort By:
Pageof 9
Mayo Clinic Proceedings|February 7, 2021
Coagulation Abnormalities in Light Chain AmyloidosisNadine Abdallah, Eli Muchtar, Angela Dispenzieri, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2023
Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple MyelomaSarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Blood Cancer Journal|November 17, 2018
Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myelomaPraful Ravi, Shaji K Kumar, Lindsey Roeker, et al.
American Journal of Hematology|February 4, 2020
Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosisSurbhi Sidana, Eli Muchtar, M Hasib Sidiqi, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2024
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel TherapiesCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple MyelomaShaji Kumar, Betsy Knopf, Erik Asmus, et al.
Blood|June 9, 2025
Eliminating the need for sequential confirmation of response in multiple myelomaJean-Sébastien Claveau, Prashant Kapoor, Moritz Binder, et al.
Leukemia|November 12, 2021
Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosisAlissa Visram, Celine Vachon, Linda B Baughn, et al.
Blood Advances|July 1, 2025
From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysisEli Muchtar, Angela Dispenzieri, Francis K Buadi, et al.
Pageof 9